DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Pharmacotherapy for schizophrenia has limitations such as residual positive and negative
symptoms, cognitive deficits and intolerable side effects. Refractory schizophrenia is still
a difficult clinical issue at present. According to the N-methyl-D-aspartate (NMDA)
hypothesis, adjuvant NMDA-enhancing agents may have therapeutic benefit. DAAOI-2, a D-amino
acid oxidase (DAAO) inhibitor, is a NMDA-enhancing agent. The aim of this project is to
examine the effectiveness and safety of DAAOI-2 add-on treatment for treatment-resistant
schizophrenia patients in a randomized, double-blind, placebo-controlled trial.